Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03048344
Recruitment Status : Completed
First Posted : February 9, 2017
Last Update Posted : March 25, 2019
Sponsor:
Information provided by (Responsible Party):
Orsenix LLC

Brief Summary:

Part 1 will be conducted as an open-label, non-randomized, non-placebo-controlled dose escalation study using pre-specified doses. Subjects with the following advanced hematological disorders and no available therapies, and who satisfy all inclusion/exclusion criteria will be enrolled. The purpose is to identify the recommended dose of oral ORH-2014 in subjects with advanced hematological disorders.

Part 2 will be an expansion phase conducted as a single-arm, open-label study to further evaluate the safety and tolerability of ORH-2014 at the maximum tolerated dose (MTD) or recommended dose determined from Part 1 in the fasted state. Subjects with the same disease types as in Part 1 will be enrolled. All subjects will receive oral ORH-2014, in the fasted state, at the recommended dose for an initial period of up to 12 weeks. The purpose is to evaluate the safety and tolerability of oral ORH-2014 in a population of subjects with advanced hematological disorders when administered at the recommended dose.


Condition or disease Intervention/treatment Phase
Advanced Hematological Disorders Drug: ORH-2014 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Part 1 of the study is parallel. Part 2 will be an expansion phase.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Actual Study Start Date : December 2, 2016
Actual Primary Completion Date : February 28, 2019
Actual Study Completion Date : February 28, 2019


Arm Intervention/treatment
Experimental: Part 1
Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.
Drug: ORH-2014
ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.

Experimental: Part 2
Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
Drug: ORH-2014
ORH-2014 capsule at recommended dose orally.




Primary Outcome Measures :
  1. To identify the recommended dose [ Time Frame: From baseline to Week 4 ]
    The recommended dose is determined by the number of patients who experience a dose limiting toxicity (DLT).

  2. Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability of ORH-2014 when administered at the MTD or recommended dose [ Time Frame: Up to Week 28 ]

    To evaluate safety and tolerability the aggregate review will include but is not limited to:

    • NCI-CTCAE Grade 3 and 4 AEs, serious adverse events (SAEs), deaths;
    • Laboratory results;
    • Vital signs;
    • ECGs;
    • Individual subject profiles including, but not limited to: medical history, AEs, concomitant medications, laboratory results, and vital signs;
    • Subject disposition and screen failure rates.


Secondary Outcome Measures :
  1. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by maximum observed concentration (Cmax) [ Time Frame: Baseline up to Week 24 ]
  2. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by time to maximum concentration (Tmax) [ Time Frame: Baseline up to Week 24 ]
  3. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent terminal elimination half-life (t1/2) [ Time Frame: Baseline up to Week 24 ]
  4. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by area under the concentration-time curve from 0 to 24 hours (AUC0-24) [ Time Frame: Baseline up to Week 24 ]
  5. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by area under the concentration-time curve extrapolated to infinity (AUC0-infinity) [ Time Frame: Baseline up to Week 24 ]
  6. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent terminal elimination rate constant (λZ) [ Time Frame: Baseline up to Week 24 ]
  7. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total clearance (CL/F) [ Time Frame: Baseline up to Week 24 ]
  8. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total clearance normalized by body weight (CL/F/kg) [ Time Frame: Baseline up to Week 24 ]
  9. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total volume of distribution (Vz/F) [ Time Frame: Baseline up to Week 24 ]
  10. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by accumulation ratio (AR) [ Time Frame: Baseline up to Week 24 ]
  11. To evaluate the effect of ORH-2014 on QT-interval corrected for heart rate using Fridericia's formula (QTcF) [ Time Frame: Baseline up to Week 28 ]
  12. Safety Assessment during the expansion phase of the study on the effect of oral ORH-2014 on safety parameters [ Time Frame: Baseline up to Week 28 ]

    During the expansion phase of the study, an aggregate clinical data review (ACDR) will be conducted. This review will collect data from electronic data capture, the ECG central review vendor (ERT), and other sources to include but is not limited to:

    • NCI-CTCAE Grade 3 and 4 AEs, SAEs, deaths;
    • Laboratory results;
    • Vital signs;
    • ECG's;
    • Individual subject profiles including, but not limited to: medical history, AEs, concomitant medications, laboratory results, and vital signs;
    • Subject disposition and screen failure rates.

  13. The number of participants with a complete response (CR) or partial response (PR) according to International Working Group (IWG) response criteria [ Time Frame: Up to Week 24 ]
    Bone marrow aspirates and/or biopsies will be obtained at the designated timepoints for evaluation of efficacy. Response criteria will be according to the International Working Group. Responders are participants who obtain complete remission (CR) or partial remission (PR), with or without cytogenetic response, and marrow complete remission.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female and male subjects ≥18 years of age with one of the following:

    • Relapsed or refractory acute myelocytic leukemia (AML) with nucleophosmin-1 (NPM1) mutations and no available therapies.
    • Relapsed or refractory acute promyelocytic leukemia (APL), with no available therapies. Note: Prior exposure to arsenic trioxide is allowed; however, subjects who have failed arsenic trioxide within the last 12 months are not allowed.
    • Relapsed or refractory myelodysplastic syndrome (MDS), International Prognostic Scoring System intermediate or high-risk, with no available therapies
    • Relapsed or refractory chronic myelomonocytic leukemia (CMML), and other MDS/myeloproliferative neoplasm (MPN) overlap syndromes, with no available therapies
    • Relapsed or refractory mantle cell lymphoma (MCL) with no adequate therapies.
  • Negative pregnancy test at the Screening visit for women of childbearing potential and willingness to use adequate birth control
  • Not willing to undergo, not a candidate for, or not having a donor for immediate (within 3 months from the Screening date) bone marrow transplantation.

Exclusion Criteria:

  • Eastern Cooperative Oncology Group performance status of ≥3;
  • Absolute myeloblast count ≥20,000/mm^3;
  • Administration of any antineoplastic therapy within 5 half-lives of the antineoplastic therapy before the first dose of ORH-2014, with the exception of hydroxyurea that should be discontinued 1 day prior to the first dose of ORH-2014
  • Presence of any remaining toxicities due to previous chemotherapy
  • Participation in other clinical trials within at least 2 weeks of the first ORH-2014 dose;
  • Clinical evidence of active central nervous system leukemia;
  • Active and uncontrolled infection
  • Major surgery within 2 weeks prior to trial entry;
  • Liver function tests above the following limits at Screening: total bilirubin >1.5 x upper limit of normal (ULN) unless related to Gilbert's syndrome or hemolysis; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x ULN; for subjects with liver involvement, AST and/or ALT >5 x ULN;
  • Serum creatinine >1.5 x ULN and/or creatinine clearance or estimated glomerular filtration rate <30 mL/min
  • Impaired cardiac function
  • Myocardial infarction of unstable angina within 6 months prior to the planned start date of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03048344


Locations
Layout table for location information
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Weill Cornell Medical College
New York, New York, United States, 10065
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37240
United States, Texas
MD Anderson
Houston, Texas, United States, 77030
Sponsors and Collaborators
Orsenix LLC
Investigators
Layout table for investigator information
Principal Investigator: Farhad Ravandi-Kashani, MD MD Anderson
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Orsenix LLC
ClinicalTrials.gov Identifier: NCT03048344    
Other Study ID Numbers: ORH2014-001
First Posted: February 9, 2017    Key Record Dates
Last Update Posted: March 25, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Orsenix LLC:
acute promyelocytic leukemia
APL
arsenic trioxide
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Diseases